Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function

Molecular Pharmacology

Volumn 81, Issue 2, 2012, Pages 120-133

  Noetzel, Meredith J ^a   Rook, Jerri M ^a   Vinson, Paige N ^a   Cho, Hyekyung P ^a,b   Days, Emily ^a   Zhou, Y ^a   Rodriguez, Alice L ^a   Lavreysen, Hilde ^c   Stauffer, Shaun R ^a,b   Niswender, Colleen M ^a   Xiang, Zixiu ^a   Daniels, J Scott ^a   Jones, Carrie K ^a   Lindsley, Craig W ^a,b   Weaver, C David ^a   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

METABOTROPIC RECEPTOR 5; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; VU0092273; VU0240382; VU0360172; VU0361747;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ASSAY; CELL LINE; CELL STRAIN HEK293; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DATA ANALYSIS; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LONG TERM DEPRESSION; MALE; MEDICAL RECORD; NERVE CELL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBTHALAMIC NUCLEUS;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; ASTROCYTES; CELL LINE; CENTRAL NERVOUS SYSTEM; HUMANS; MICE; NEURONS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84862964996     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.075184     Document Type: Article

References (43)

1. Awad H, Hubert GW, Smith Y, Levey AI, and Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
2. Ayala JE, Chen Y, Banko JL, Sheffler DJ, Williams R, Telk AN, Watson NL, Xiang Z, Zhang Y, Jones PJ, et al. (2009) mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 34:2057-2071.
3. Bear MF, Huber KM, and Warren ST (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377. (Pubitemid 38829251)
4. Chen Y, Goudet C, Pin JP, and Conn PJ (2008) N-{4-Chloro-2-[(1,3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol Pharmacol 73:909-918. (Pubitemid 351397895)
5. Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, and Conn PJ (2007) Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol Pharmacol 71:1389-1398. (Pubitemid 46661543)
6. Cohen AS, Raymond CR, and Abraham WC (1998) Priming of long-term potentiation induced by activation of metabotropic glutamate receptors coupled to phospholipase C. Hippocampus 8:160-170. (Pubitemid 28171897)
7. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
8. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237. (Pubitemid 27238875)
9. Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, and Collingridge GL (2000) A novel, competitive mGlu5 receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. Br J Pharmacol 131:239-244.
10. Faas GC, Adwanikar H, Gereau RW 4th, and Saggau P (2002) Modulation of presynaptic calcium transients by metabotropic glutamate receptor activation: a differential role in acute depression of synaptic transmission and long-term depression. J Neurosci 22:6885-6890. (Pubitemid 35379146)
11. Ghoneim MM, Hinrichs JV, Mewaldt SP, and Petersen RC (1985) Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol 5:70-77. (Pubitemid 15149495)
12. Hirose K and Chan PH (1993) Blockade of glutamate excitotoxicity and its clinical applications. Neurochem Res 18:479-483. (Pubitemid 23111248)
13. Huang CC and Hsu KS (2006) Sustained activation of metabotropic glutamate receptor 5 and protein tyrosine phosphatases mediate the expression of (S)-3,5-dihydroxyphenylglycine-induced long-term depression in the hippocampal CA1 region. J Neurochem 96:179-194.
14. Huber KM, Gallagher SM, Warren ST, and Bear MF (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99:7746-7750. (Pubitemid 34568762)
15. Huber KM, Roder JC, and Bear MF (2001) Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1. J Neurophysiol 86:321-325. (Pubitemid 32623237)
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60:24-35.
18. Kerner JA, Standaert DG, Penney JB Jr, Young AB, and Landwehrmeyer GB (1997) Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Brain Res Mol Brain Res 48:259-269. (Pubitemid 27390062)
19. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199-206. (Pubitemid 40411343)
20. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214. (Pubitemid 24081509)
21. Lauterborn JC, Rex CS, Kramár E, Chen LY, Pandyarajan V, Lynch G, and Gall CM (2007) Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 27:10685-10694. (Pubitemid 47535868)
22. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, and Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234-242.
23. Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, et al. (2008) ADX47273 [S-(4-fluoro-phenyl)- {3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther 327:827-839.
24. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, and Roder JC (1997) Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17:5196-5205. (Pubitemid 27263833)
25. Malenka RC and Bear MF (2004) LTP and LTD: an embarrassment of riches. Neuron 44:5-21. (Pubitemid 39348827)
26. Mannaioni G, Marino MJ, Valenti O, Traynelis SF, and Conn PJ (2001) Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 21:5925-5934. (Pubitemid 32737725)
27. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, and Schoemaker H (2010) Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77:317-326.
28. Niswender CM and Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295-322.
29. Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ, and Weaver CD (2008) A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Mol Pharmacol 73:1213-1224. (Pubitemid 351439203)
30. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, et al. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 309:568-577. (Pubitemid 38542609)
31. Peavy RD and Conn PJ (1998) Phosphorylation of mitogen-activated protein kinase in cultured rat cortical glia by stimulation of metabotropic glutamate receptors. J Neurochem 71:603-612. (Pubitemid 28480407)
32. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, Bernardi G, and Calabresi P (2001) Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106:579-587. (Pubitemid 32925246)
33. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, et al. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 78:1105-1123.
34. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, and Conn PJ (2005) A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 68:1793-1802. (Pubitemid 41654362)
35. Schann S, Mayer S, Franchet C, Frauli M, Steinberg E, Thomas M, Baron L, and Neuville P (2010) Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators. J Med Chem 53:8775-8779.
36. Schlumberger C, Schäfer D, Barberi C, Morè L, Nagel J, Pietraszek M, Schmidt WJ, and DanyszW(2009) Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol 20:56-66.
37. Sharma S, Kedrowski J, Rook JM, Smith RL, Jones CK, Rodriguez AL, Conn PJ, and Lindsley CW (2009) Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. J Med Chem 52:4103-4106.
38. Testa CM, Standaert DG, Landwehrmeyer GB, Penney JB Jr, and Young AB (1995) Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. J Comp Neurol 354:241-252.
39. Varnes JG, Marcus AP, Mauger RC, Throner SR, Hoesch V, King MM, Wang X, Sygowski LA, Spear N, Gadient R, et al. (2011) Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorg Med Chem Lett 21:1402-1406.
40. Vinson PN and Conn PJ (2011) Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology doi:10.1016/j. neuropharm.2011.05.005.
41. Wan H, Rehngren M, Giordanetto F, Bergström F, and Tunek A (2007) High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50:4606-4615. (Pubitemid 47463235)
42. Williams R, Manka JT, Rodriguez AL, Vinson PN, Niswender CM, Weaver CD, Jones CK, Conn PJ, Lindsley CW, and Stauffer SR (2011) Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. Bioorg Med Chem Lett 21:1350-1353.
43. Zhang Y, Rodriguez AL, and Conn PJ (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther 315:1212-1219. (Pubitemid 41635410)